Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 7/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 8/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | HTR2B | P41595 | 4/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100411 | 0.95 | KCNN4 (0.41) | KCNN4KCNH2HRH3HTR2CHTR2A | |
| SCHEMBL10100755 | 0.93 | HTR2C (0.40) | KCNN4HTR2CHTR2BABCB1ABCG2 | |
| SCHEMBL10100769 | 0.89 | MCHR1 (0.39) | KCNN4HTR2CHTR2AHTR2BMCHR1 | |
| SCHEMBL10100767 | 0.89 | MCHR1 (0.40) | HTR2CHTR2AHTR2BMCHR1 | |
| SCHEMBL10100768 | 0.88 | ADORA2A (0.38) | KCNN4HTR2CHTR2AHTR2BMCHR1 | |
| SCHEMBL10100720 | 0.88 | MCHR1 (0.40) | HTR2CMCHR1SMN1; SMN2 | |
| SCHEMBL10100709 | 0.88 | SMN1; SMN2 (0.38) | KCNN4HTR2CHTR2AHTR2BKDM4E | |
| SCHEMBL10100565 | 0.87 | HTR2C (0.41) | KCNN4HTR2CHTR2BABCB1ABCG2 | |
| SCHEMBL10100712 | 0.87 | SMN1; SMN2 (0.43) | HTR2CHTR2AHTR2BMCHR1KDM4E | |
| SCHEMBL10100711 | 0.87 | BMPR1B (0.37) | HRH3HTR2CHTR2AHTR2BMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | KCNN4 4066/4885KCNH2 3514/4885HRH3 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.